

Table S1: Lymphocyte Subsets Quantitated During 24 weeks of Exposure to tabalumab and 52 weeks of Follow-up

Cell Type: Blood and Tonsil	Phenotype
Total B cells	CD19+CD3-
Total T cells	CD3+
Mature Naïve B cells	CD19+CD27neg IgD+ CD10neg
Isotype Switched Memory B cells	CD19+CD27+ IgDneg
Unswitched Memory B cells	CD19+ CD27+ IgD+
Immature B cells	CD19+CD27neg IgDneg
T-Helper/Inducer cells	CD3+CD4+
T-Suppressor/Cytotoxic cells	CD3+CD8+
Transitional B cells – subset 1	CD19+ CD38++/+++ CD24++++/+ CD10+
Transitional B cells – subset 2	CD19+CD27-IgD+CD10+)
T Follicular Helper (TFH) cells	CD3+ CD4+ CXCR5+ PD-1+)
Plasma cells	CD38+++ vs SSC
CD4+ Naïve T cells	CD3+CD4+CCR7+CD45RA+
CD4+ Central Memory T cells	CD3+CD4+CD62L+CCR7+CD45RA-
CD4+ Effector Memory T cells	CD3+CD4+CD62L+CCR7-CD45RA-/+
CD8+ Naïve T cells	CD3+CD8+CCR7+CD45RA+
CD8+ Central Memory T cells	CD3+CD8+CD62L+CCR7+CD45RA-
CD8+ Effector Memory T cells	CD3+CD8+CD62L+CCR7-CD45RA-/+
Cell Type: Tonsil	Phenotype
Germinal Center B cells: Bm2'	CD19+ CD38+ IgD+
Germinal Center B cells: Bm3, Bm4	CD19+ CD38+ IgDneg

Table S2: Serious Adverse Event Summary

	Tabalumab (LY2127399)	
	Affected / at Risk (%)	# Events
Total	9/18 (50%)	
Blood and lymphatic system disorders		
Anaemia	1/18 (5.56%)	1
Cardiac disorders		
Arrhythmia / Death	1/18 (5.56%)	1
Cardiac tamponade	1/18 (5.56%)	1
Cardio-respiratory arrest / Death	1/18 (5.56%)	1
Pericardial effusion	1/18 (5.56%)	1
Endocrine disorders		
Hyperparathyroidism	1/18 (5.56%)	1
Gastrointestinal disorders		
Haemorrhoidal haemorrhage	1/18 (5.56%)	1
General disorders		
Chest pain	1/18 (5.56%)	1
Infections and infestations		
Lobar pneumonia	1/18 (5.56%)	1
Peritonitis	1/18 (5.56%)	1
Pneumonia	1/18 (5.56%)	1
Sepsis	1/18 (5.56%)	1
Metabolism and nutrition disorders		
Decreased appetite	1/18 (5.56%)	1
Nervous system disorders		
Cerebrovascular accident	1/18 (5.56%)	1
Neuropathy peripheral	1/18 (5.56%)	1
Toxic encephalopathy	1/18 (5.56%)	1
Transient ischaemic attack	1/18 (5.56%)	1
VIIth nerve paralysis	1/18 (5.56%)	1

Table S3: Adverse Event Summary: Other (Not Including Serious) Adverse Events, Frequency Threshold of 5%

	Tabalumab (LY2127399)	
	Affected / at Risk (%)	# Events
Total	18/18 (100%)	
Blood and lymphatic system disorders		
Anaemia	2/18 (11.11%)	2
Cardiac disorders		
Atrial fibrillation	1/18 (5.56%)	1
Left ventricular hypertrophy	1/18 (5.56%)	1
Ear and labyrinth disorders		
Vertigo	1/18 (5.56%)	1
Endocrine disorders		
Hyperparathyroidism	2/18 (11.11%)	2
Eye disorders		
Vision blurred	1/18 (5.56%)	1
Gastrointestinal disorders		
Abdominal pain	1/18 (5.56%)	1
Abdominal pain upper	1/18 (5.56%)	1
Ascites	1/18 (5.56%)	1
Constipation	1/18 (5.56%)	1
Diarrhoea	1/18 (5.56%)	1
Faecal incontinence	1/18 (5.56%)	1
Nausea	1/18 (5.56%)	1
Peptic ulcer	1/18 (5.56%)	1
Vomiting	2/18 (11.11%)	2
General disorders		
Catheter site pain	1/18 (5.56%)	1
Chest discomfort	1/18 (5.56%)	1
Fatigue	1/18 (5.56%)	1
Feeling abnormal	1/18 (5.56%)	1
Injection site extravasation	2/18 (11.11%)	3
Injection site pain	17/18 (94.44%)	83
Medical device complication	1/18 (5.56%)	1

Oedema peripheral	3/18 (16.67%)	3
Pain	1/18 (5.56%)	1
Pyrexia	1/18 (5.56%)	1
Thrombosis in device	1/18 (5.56%)	1
Hepatobiliary disorders		
Bile duct stone	1/18 (5.56%)	1
Immune system disorders		
Kidney transplant rejection	1/3 (33.3%)	1
Seasonal allergy	1/18 (5.56%)	1
Infections and infestations		
Bronchitis	2/18 (11.11%)	5
Clostridium difficile infection	1/18 (5.56%)	1
Ear infection	1/18 (5.56%)	1
Labyrinthitis	1/18 (5.56%)	1
Lobar pneumonia	1/18 (5.56%)	1
Nasopharyngitis	1/18 (5.56%)	1
Upper respiratory tract infection	2/18 (11.11%)	2
Injury, poisoning and procedural complications		
Arteriovenous fistula aneurysm	1/18 (5.56%)	1
Arteriovenous fistula site complication	1/18 (5.56%)	1
Hand fracture	1/18 (5.56%)	1
Post procedural discomfort	3/18 (16.67%)	3
Procedural hypotension	2/18 (11.11%)	2
Procedural pain	2/18 (11.11%)	2
Rib fracture	1/18 (5.56%)	1
Spinal compression fracture	1/18 (5.56%)	1
Investigations		
Cardiac murmur	1/18 (5.56%)	1
Lipase increased	1/18 (5.56%)	1
Weight decreased	1/18 (5.56%)	1
Metabolism and nutrition disorders		
Hypercholesterolaemia	1/18 (5.56%)	1
Hyperphosphataemia	1/18 (5.56%)	1
Hypoalbuminaemia	1/18 (5.56%)	1
Hypocalcaemia	1/18 (5.56%)	1
Hypokalaemia	3/18 (16.67%)	3

Malnutrition	1/18 (5.56%)	1
Musculoskeletal and connective tissue disorders		
Arthralgia	1/18 (5.56%)	1
Muscle spasms	2/18 (11.11%)	2
Musculoskeletal discomfort	1/18 (5.56%)	1
Pain in extremity	1/18 (5.56%)	1
Nervous system disorders		
Convulsion	1/18 (5.56%)	1
Dizziness	1/18 (5.56%)	1
Dysgeusia	1/18 (5.56%)	1
Headache	1/18 (5.56%)	1
Hypoaesthesia	1/18 (5.56%)	1
Migraine	1/18 (5.56%)	1
Syncope	2/18 (11.11%)	2
Uraemic neuropathy	1/18 (5.56%)	1
Psychiatric disorders		
Anxiety	1/18 (5.56%)	1
Communication disorder	1/18 (5.56%)	1
Depression	1/18 (5.56%)	1
Renal and urinary disorders		
Renal pain	1/18 (5.56%)	1
Reproductive system and breast disorders		
Uterine cyst	1/10 (10%)	1
Respiratory, thoracic and mediastinal disorders		
Lung infiltration	1/18 (5.56%)	1
Oropharyngeal pain	3/18 (16.67%)	3
Pulmonary hypertension	1/18 (5.56%)	1
Skin and subcutaneous tissue disorders		
Dermatitis	1/18 (5.56%)	1
Rash	2/18 (11.11%)	2
Vascular disorders		
Hypotension	5/18 (27.78%)	7
Iliac vein occlusion	1/18 (5.56%)	1
Thrombophlebitis	1/18 (5.56%)	1